<?xml version="1.0" encoding="UTF-8"?><doi_batch version="4.3.7" xmlns="http://www.crossref.org/schema/4.3.7" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.crossref.org/schema/4.3.7 http://www.crossref.org/schema/deposit/crossref4.3.7.xsd">
		<head>
		<doi_batch_id>eamdacademy.org-b7SU-1792236768-r234545485</doi_batch_id>
		<timestamp>1792236768</timestamp>
		<depositor>
			<depositor_name>Eurasian Academy of Medicine and Dentistry</depositor_name>
			<email_address>info@eamdacademy.org</email_address>
		</depositor>
		<registrant>Eurasian Academy of Medicine and Dentistry</registrant>
	</head>
	<body>
		<journal>
			<journal_metadata>
				<full_title>Journal of Applied Pharmaceutical Technologies and Systems</full_title>
				<abbrev_title>J Appl Pharm Technol Syst</abbrev_title>
				<issn>3149-9589</issn>
			</journal_metadata>
			<journal_issue>
				<publication_date>
					<year>2024</year>
				</publication_date>
				<journal_volume>
					<volume>3</volume>
				</journal_volume>
				<issue>1</issue>
			</journal_issue>
			<journal_article publication_type="full_text">
				<titles>
					<title>Integrating Formulation Design, Process Control, and Patient-Centric Performance in Applied Pharmaceutical Technologies</title>
				</titles>
								<contributors>
          					<person_name sequence="first" contributor_role="author">
            <given_name>Lucas</given_name>
            <surname>Meyer</surname>
					</person_name>
          					<person_name sequence="additional" contributor_role="author">
            <given_name>Anna</given_name>
            <surname>Schmid</surname>
					</person_name>
          					<person_name sequence="additional" contributor_role="author">
            <given_name>Stefan</given_name>
            <surname>Braun</surname>
					</person_name>
          				</contributors>
								<publication_date>
					<year>2024</year>
				</publication_date>
				<doi_data>
					<doi>10.68159/r234545485</doi>
					<resource>https://eamdacademy.org/pub/journal/3/article/r234545485</resource>
				</doi_data>
				<citation_list>
          					<citation key="rk-10.68159/r234545485-9d3aa221-0a25-4b02-b10d-a84c0a3a157c">
					  <unstructured_citation>Djuris J, Djuric Z. Modeling in the quality by design environment: Regulatory requirements and recommendations for design space and control strategy appointment. Int J Pharm. 2017;533(2):346-56.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-d23e07da-8967-4863-8366-645c8ff428db">
					  <unstructured_citation>Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. Int J Pharm.. 2021;602:120554.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-6aad2a43-be36-4a57-9e23-ab27f1fd030c">
					  <unstructured_citation>Menditto E, Orlando V, De Rosa G, Minghetti P, Musazzi UM, Cahir C, et al. Patient centric pharmaceutical drug product design—The impact on medication adherence. Pharmaceutics. 2020;12(1):44.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-9860e588-73c0-48f0-8fd6-f2181571ce10">
					  <unstructured_citation>Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat Rev Drug Discov. 2023;22(5):387-409.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-d2370706-6028-43cb-a9c5-5df2163d5aa9">
					  <unstructured_citation>Algorri M, Cauchon NS, Christian T, O&#039;Connell C, Vaidya P. Patient-centric product development: a summary of select regulatory CMC and device considerations. J Pharm Sci. 2023;112(4):922-36.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-15c37a0f-ab56-4efb-8ddc-f8add497c3da">
					  <unstructured_citation>Van Snick B, Holman J, Cunningham C, Kumar A, Vercruysse J, De Beer T, et al. Continuous direct compression as manufacturing platform for sustained release tablets. J Pharm Sci. 2017;519(1-2):390-407.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-8ec3a593-3905-4b33-a795-fe5550feed10">
					  <unstructured_citation>Grymonpré W, Bostijn N, Van Herck S, Verstraete G, Vanhoorne V, Nuhn L, et al. Downstream processing from hot-melt extrusion towards tablets: A quality by design approach.Int J Pharm. 2017;531(1):235-45.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-84d99e99-06fb-4dec-9bc3-fa5516678da3">
					  <unstructured_citation>Butreddy A, Bandari S, Repka MA. Quality-by-design in hot melt extrusion based amorphous solid dispersions: An industrial perspective on product development. Eur J Pharm Sci. 2021;158:105655.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-7a884823-ce00-48fd-af5f-0ef768875e5a">
					  <unstructured_citation>Davis MT, Potter CB, Walker GM. Downstream processing of a ternary amorphous solid dispersion: The impacts of spray drying and hot melt extrusion on powder flow, compression and dissolution. Int J Pharm. 2018;544(1):242-53.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-2c33a989-0464-45d2-b5af-508ff3621c96">
					  <unstructured_citation>Sakai T, Hirai D, Kimura SI, Iwao Y, Itai S. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions. Int J Pharm. 2018;540(1-2):171-7.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-0538bd72-cdaa-4a37-b067-e324887d324a">
					  <unstructured_citation>Namjoshi S, Dabbaghi M, Roberts MS, Grice JE, Mohammed Y. Quality by design: Development of the quality target product profile (QTPP) for semisolid topical products. Pharmaceutics. 2020;12(3):287.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-22cee2ce-7a77-4317-8107-6325e7b720c3">
					  <unstructured_citation>Tsiligiannis A, Sfouni M, Nalda-Molina R, Dokoumetzidis A. Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis. Eur J Pharm Sci. 2019;138:105016.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-b82b067f-d269-4fc2-be13-3c1051b1bfc2">
					  <unstructured_citation>Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front pharmacol. 2021;12:618411.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-a9614471-9d38-46f0-a638-973382c16979">
					  <unstructured_citation>Xu Y, Zhao M, Cao J, Fang T, Zhang J, Zhen Y, et al. Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis. APSB. 2023;13(11):4417-41.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-e0d15d54-639a-430d-a21e-9974927e1470">
					  <unstructured_citation>Simões A, Veiga F, Vitorino C. Question-based review for pharmaceutical development: An enhanced quality approach. Eur J Pharm Biopharm. 2024;195:114174.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-f31810da-c50f-42cc-8046-90c46253c994">
					  <unstructured_citation>Rocha B, de Morais LA, Viana MC, Carneiro G. Promising strategies for improving oral bioavailability of poor water-soluble drugs. Expert Opin Drug Discov. 2023;18(6):615-27.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-5c03d52c-e75b-4d30-a22c-c5ce7178f64c">
					  <unstructured_citation>Bhaskar A, Barros FN, Singh R. Development and implementation of an advanced model predictive control system into continuous pharmaceutical tablet compaction process.Int J Pharm. 2017;534(1-2):159-78.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-d543250f-fd89-49ec-917c-20c90924d6d5">
					  <unstructured_citation>Mesbah A, Paulson JA, Lakerveld R, Braatz RD. Model predictive control of an integrated continuous pharmaceutical manufacturing pilot plant. OPR&amp;D. 2017;21(6):844-54.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-18779170-42d5-43e8-b563-ed7f5b3e5fef">
					  <unstructured_citation>Li Y, Anderson CA, Drennen III JK, Airiau C, Igne B. Method development and validation of an inline process analytical technology method for blend monitoring in the tablet feed frame using Raman spectroscopy. Anal Chem. 2018;90(14):8436-44.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-29daaa07-566a-456e-8260-04927f7b7fa0">
					  <unstructured_citation>Markl D, Warman M, Dumarey M, Bergman EL, Folestad S, Shi Z, et al. Review of real-time release testing of pharmaceutical tablets: State-of-the art, challenges and future perspective. Int J Pharm. 2020;582:119353.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-6948f82c-c204-4efa-a800-a832d28a8b85">
					  <unstructured_citation>Su Q, Ganesh S, Moreno M, Bommireddy Y, Gonzalez M, Reklaitis GV, Nagy ZK. A perspective on Quality-by-Control (QbC) in pharmaceutical continuous manufacturing. Comput Chem Eng. 2019;125:216-31.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-d22c4bd5-8b44-45f0-b1dd-5acb46854d94">
					  <unstructured_citation>Barenji RV, Akdag Y, Yet B, Oner L. Cyber-physical-based PAT (CPbPAT) framework for Pharma 4.0. Int J Pharm. 2019;567:118445.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-dc3dfaf5-a5aa-4091-8a27-023f5cccaec7">
					  <unstructured_citation>Roggo Y, Jelsch M, Heger P, Ensslin S, Krumme M. Deep learning for continuous manufacturing of pharmaceutical solid dosage form. Eur J Pharm Biopharm. 2020;153:95-105.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-7dd52b91-64ce-409a-a64e-6287d1db4e77">
					  <unstructured_citation>Sacher S, Poms J, Rehrl J, Khinast JG. PAT implementation for advanced process control in solid dosage manufacturing–a practical guide. Int J Pharm. 2022;613:121408.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-2be3c4e0-4750-4aa3-8887-7ee00251a6c9">
					  <unstructured_citation>Domokos A, Nagy B, Szilágyi B, Marosi G, Nagy ZK. Integrated continuous pharmaceutical technologies—a review. OPR&amp;D. 2021;25(4):721-39.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-0fc77d08-86a5-4611-825a-fbe8e57e8747">
					  <unstructured_citation>Shariff Z, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I. Patient-centric medicine design: key characteristics of oral solid dosage forms that improve adherence and acceptance in older people. Pharmaceutics. 2020;12(10):905.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-9ba519aa-4df0-4625-ac29-257d0f039484">
					  <unstructured_citation>Shariff ZB, Dahmash DT, Kirby DJ, Missaghi S, Rajabi-Siahboomi A, Maidment ID. Does the formulation of oral solid dosage forms affect acceptance and adherence in older patients? A mixed methods systematic review. OPR&amp;D. 2020;21(8):1015-23.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-392aebed-4bf9-4779-bfd8-5bb63c22b5d3">
					  <unstructured_citation>Mu Y, Zhao L, Shen L. Medication adherence and pharmaceutical design strategies for pediatric patients: An overview. Drug Discov Today. 2023;28(11):103766.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-3ed9c848-35c0-46b1-ac14-5d0eda2b01be">
					  <unstructured_citation>Hauber B, Hand MV, Hancock BC, Zarrella J, Harding L, Ogden-Barker M, et al. Patient acceptability and preferences for solid oral dosage form drug product attributes: a scoping review. Patient Prefer Adherence. 2024:1281-97.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-dcf5730a-2c2a-40de-ae23-d4fa2aba8184">
					  <unstructured_citation>Grangeia HB, Silva C, Simoes SP, Reis MS. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives. Eur J Pharm Biopharm. 2020;147:19-37.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-139ee621-5802-4da5-8746-3770c3fb7583">
					  <unstructured_citation>Sultan T, Rozin EH, Paul S, Tseng YC, Dave VS, Cetinkaya C. Machine learning modeling for ultrasonic quality attribute assessment of pharmaceutical tablets for continuous manufacturing and real-time release testing. Int J Pharm. 2024;655:124049.</unstructured_citation>
											</citation>
          					<citation key="rk-10.68159/r234545485-6019093a-20fb-48d3-8799-5ee67929931d">
					  <unstructured_citation>Otsuka M, Ogata T, Hattori Y, Sasaki T. Evaluation of the effect of granule size of raw tableting materials on critical quality attributes of tablets during the continuous tablet manufacturing process using near-infrared spectroscopy. Drug Dev Ind Pharm. 2023;49(11):692-702.</unstructured_citation>
											</citation>
          				</citation_list>
			</journal_article>
		</journal>
	</body>
</doi_batch>
